All In Biotech

Drug Trial Radar · NCT07608705

A Study to Assess the Effect of HRS-1301 on the Pharmacokinetics of Midazolam and Atorvastatin in Healthy Participants

An Open-label, Single-arm, Fixed-sequence Phase I Clinical Trial to Evaluate the Effect of HRS-1301 Tablets on the Pharmacokinetics of Midazolam and Atorvastatin Calcium Tablets in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Jun 8, 2026

Primary completion

Aug 24, 2026

Study completion Aug 24, 2026

Sponsor

Sponsor type
Industry
First posted
May 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This phase I study in healthy participants aims to assess the pharmacokinetics of midazolam and atorvastatin when administered alone and in combination with HRS-1301, and to assess the safety of HRS-1301 when administered alone and in combination with midazolam or atorvastatin.

Conditions

  • Hyperlipidemias

Interventions

  • HRS-1301 TabletsDrug

    HRS-1301 tablets.

  • Atorvastatin Calcium TabletsDrug

    Atorvastatin Calcium tablets.

  • Midazolam oral solutionDrug

    Midazolam oral solution.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum observed plasma concentration (Cmax)Time frame: Up to 15 days.
  2. Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC 0-last)Time frame: Up to 15 days.
  3. Area under the plasma concentration-time curve from time 0 to infinity (AUC 0-inf)Time frame: Up to 15 days.
  4. Maximum observed plasma concentration (Cmax)Time frame: Up to 18 days.
  5. Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC0-last)Time frame: Up to 18 days.
  6. Area under the plasma concentration-time curve from time 0 to infinity (AUC 0-inf)Time frame: Up to 18 days.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.